Renaissance Technologies’s Eterna Therapeutics ERNA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q2
Sell
-27
Closed -$24K 3609
2024
Q1
$24K Buy
+27
New +$18.6K ﹤0.01% 3573
2023
Q2
Sell
-35
Closed -$44K 4017
2023
Q1
$44K Sell
35
-12
-26% -$18.1K ﹤0.01% 3686
2022
Q4
$56K Sell
47
-148
-76% -$209K ﹤0.01% 3777
2022
Q3
$360K Buy
195
+33
+20% +$114K ﹤0.01% 3112
2022
Q2
$629K Buy
162
+84
+108% +$603K ﹤0.01% 3015
2022
Q1
$1.19M Buy
78
+38
+95% +$721K ﹤0.01% 2616
2021
Q4
$1.24M Buy
+40
New +$2.18M ﹤0.01% 2490
2021
Q2
Sell
-3
Closed -$74K 3537
2021
Q1
$74K Buy
+3
New +$162K ﹤0.01% 3236
2020
Q4
Sell
-7
Closed -$167K 3462
2020
Q3
$167K Sell
7
-1
-13% -$30.1K ﹤0.01% 3143
2020
Q2
$253K Buy
8
+4
+100% +$86.9K ﹤0.01% 3097
2020
Q1
$94K Hold
4
﹤0.01% 3239
2019
Q4
$131K Hold
4
﹤0.01% 3266
2019
Q3
$193K Hold
4
﹤0.01% 3159
2019
Q2
$206K Buy
4
+1
+33% +$52.4K ﹤0.01% 3297
2019
Q1
$201K Hold
3
﹤0.01% 3210
2018
Q4
$89K Hold
3
﹤0.01% 3245
2018
Q3
$215K Hold
3
﹤0.01% 3130
2018
Q2
$216K Hold
3
﹤0.01% 3060
2018
Q1
$332K Hold
3
﹤0.01% 3041
2017
Q4
$194K Hold
3
﹤0.01% 3142
2017
Q3
$265K Hold
3
﹤0.01% 2934
2017
Q2
$283K Buy
3
+1
+50% +$108K ﹤0.01% 2919
2017
Q1
$294K Hold
2
﹤0.01% 2911
2016
Q4
$214K Buy
2
+1
+100% +$120K ﹤0.01% 2984
2016
Q3
$148K Hold
1
﹤0.01% 3125
2016
Q2
$158K Hold
1
﹤0.01% 3092
2016
Q1
$124K Hold
1
﹤0.01% 3178
2015
Q4
$130K Hold
1
﹤0.01% 3080
2015
Q3
$268K Hold
1
﹤0.01% 2809
2015
Q2
$182K Hold
1
﹤0.01% 2999
2015
Q1
$326K Hold
1
﹤0.01% 2736
2014
Q4
$345K Hold
1
﹤0.01% 2537
2014
Q3
$258K Hold
1
﹤0.01% 2512
2014
Q2
$408K Hold
1
﹤0.01% 2389
2014
Q1
$481K Hold
1
﹤0.01% 2370
2013
Q4
$451K Hold
1
﹤0.01% 2385
2013
Q3
$239K Hold
1
﹤0.01% 2521
2013
Q2
$274K Buy
+1
New +$262K ﹤0.01% 2427

Other funds holding ERNA

Renaissance Technologies's ERNA Position: Q2 2024 in Review

Renaissance Technologies sold out of Eterna Therapeutics (ERNA) in Q2 2024, closing a stake of 27 shares — an estimated $24K sold.

Renaissance Technologies first reported a position in ERNA in Q2 2013 and held it in 38 quarters. The position peaked at $1.24M in Q4 2021. 11 funds tracked by Wall St. Rank hold ERNA as of Q2 2024.

  • Renaissance Technologies reported no remaining Eterna Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Renaissance Technologies sold 27 Eterna Therapeutics shares in Q2 2024, an estimated $24K.
  • Renaissance Technologies first reported a position in Eterna Therapeutics in Q2 2013 and held it in 38 quarters.
  • Renaissance Technologies's Eterna Therapeutics position peaked at $1.24M in Q4 2021.
  • 11 funds tracked by Wall St. Rank held Eterna Therapeutics as of Q2 2024.

Based on Renaissance Technologies's 13F filing for Q2 2024, filed 9 Aug 2024.